Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1954 1
1955 1
1957 1
1958 2
1959 1
1962 2
1964 2
1965 1
1966 1
1967 1
1968 4
1969 1
1970 4
1971 3
1972 7
1973 2
1974 4
1975 18
1976 15
1977 16
1978 15
1979 14
1980 7
1981 14
1982 19
1983 20
1984 21
1985 28
1986 33
1987 28
1988 24
1989 31
1990 28
1991 28
1992 43
1993 37
1994 44
1995 37
1996 55
1997 45
1998 49
1999 44
2000 48
2001 51
2002 63
2003 54
2004 55
2005 57
2006 80
2007 66
2008 70
2009 66
2010 80
2011 77
2012 102
2013 100
2014 116
2015 113
2016 126
2017 113
2018 113
2019 110
2020 137
2021 150
2022 121
2023 128
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

2,715 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
Approximately 15% of patients with ET or polycythemia vera (PV) might progress into post-ET/PV MF. MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib therapy. ...RISK STRATIFICATION …
Approximately 15% of patients with ET or polycythemia vera (PV) might progress into post-ET/PV MF. MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 m …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
RAS/CBL mutations predicted resistance to ruxolitinib therapy. ADVERSE KARYOTYPE: Very high risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p-, and 11q-. RISK STRATIFICATION: Two new prognostic systems for PMF have recently been introduced: GIPSS (genetically-i …
RAS/CBL mutations predicted resistance to ruxolitinib therapy. ADVERSE KARYOTYPE: Very high risk abnormalities include -7, inv (3), i …
Infectious Mononucleosis: diagnosis and clinical interpretation.
Naughton P, Healy M, Enright F, Lucey B. Naughton P, et al. Br J Biomed Sci. 2021 Jul;78(3):107-116. doi: 10.1080/09674845.2021.1903683. Epub 2021 Apr 14. Br J Biomed Sci. 2021. PMID: 33721513 Review.
Correct and prompt diagnosis of IM can help prevent the unnecessary administration of antibiotics and mitigate the need for other expensive exploratory tests in cases of IM that present with splenomegaly, lymphadenopathy, or suspect haematological conditions. ...
Correct and prompt diagnosis of IM can help prevent the unnecessary administration of antibiotics and mitigate the need for other expensive …
Clinico-haematological profile of patients with bicytopenia.
Singh A, Hungund B, Kumar L, Pattanshetti M. Singh A, et al. Pathology. 2018 Aug;50(5):540-548. doi: 10.1016/j.pathol.2018.03.008. Epub 2018 Jul 4. Pathology. 2018. PMID: 30032928
The most common bicytopenia observed was anaemia with thrombocytopenia (61%) followed by anaemia with leukopenia (26%) and leukopenia with thrombocytopenia (13%). ...Pallor, bleeding, hepatomegaly and splenomegaly were most frequent in non-malignant conditions (p &l …
The most common bicytopenia observed was anaemia with thrombocytopenia (61%) followed by anaemia with leukopenia (26%) and leukopenia …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease; in case of intermediate-1 disease, ruxolitinib is recommended in highly symptomatic splenomegaly. Allogeneic stem cell transplantat …
Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease …
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Ikezoe T, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Villarrubia J, Chen Y, Furey S, Thurberg BL, Zaher A, Kumar M. Wasserstein M, et al. Genet Med. 2022 Jul;24(7):1425-1436. doi: 10.1016/j.gim.2022.03.021. Epub 2022 Apr 26. Genet Med. 2022. PMID: 35471153 Free article. Clinical Trial.
Primary efficacy endpoints were percent change from baseline to week 52 in percent predicted diffusing capacity of the lung for carbon monoxide and spleen volume (combined with splenomegaly-related score in the United States). ...Splenomegaly-related …
Primary efficacy endpoints were percent change from baseline to week 52 in percent predicted diffusing capacity of the lung for carbo …
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Kröger N, et al. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. Lancet Haematol. 2024. PMID: 38061384 Review.
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the management of patients with myelofibrosis. ...Key recommendations in this update include: patients with primary myelofibrosis and an interme …
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the …
Are transplant indications changing for myelofibrosis?
Palmer J. Palmer J. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):676-681. doi: 10.1182/hematology.2023000453. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066916 Review.
Myelofibrosis is a devastating myeloid malignancy characterized by dysregulation of the JAK-STAT pathway, resulting in splenomegaly, constitutional symptoms, anemia, thrombocytopenia, leukocytosis, and an increased likelihood of progression to acute leukemia. ...In this re …
Myelofibrosis is a devastating myeloid malignancy characterized by dysregulation of the JAK-STAT pathway, resulting in splenomegaly, …
Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D, Rippel N, Feld J, El Jamal SM, Mascarenhas J. Tremblay D, et al. Oncologist. 2021 May;26(5):406-421. doi: 10.1002/onco.13769. Epub 2021 Apr 21. Oncologist. 2021. PMID: 33792103 Free PMC article. Review.
Numerous prognostic scoring systems exist, some of which incorporate mutational information. Treatment ranges from observation to allogeneic hematopoietic stem cell transplantation. Therapies include hydroxyurea for cytoreduction, hypomethylating agents, and …
Numerous prognostic scoring systems exist, some of which incorporate mutational information. Treatment ranges from observat …
Chronic myelomonocytic leukemia diagnosis and management.
Chan O, Renneville A, Padron E. Chan O, et al. Leukemia. 2021 Jun;35(6):1552-1562. doi: 10.1038/s41375-021-01207-3. Epub 2021 Mar 13. Leukemia. 2021. PMID: 33714974 Review.
A number of risk stratification systems have been developed and validated but using those that incorporate molecular information such as CMML Prognostic Scoring System (CPSS)-Mol, Mayo Molecular, and Groupe Francophone des Myelodysplasies (GFM) are preferred. ...Out …
A number of risk stratification systems have been developed and validated but using those that incorporate molecular information such as CMM …
2,715 results